Virtici Announces a New Spin-out, Rise Therapeutics, Focused on Microbiome Platform Technologies for the Development of Immunological-based Therapies

Virtici, LLC announced today the spin-out of a new drug development company, Rise Therapeutics, which is focused on developing microbiome-based, immunological therapies. To form the spin-out, Rise obtained key microbiome-related intellectual property and technologies incubated at Virtici to support the development of first-in-class, orally-delivered, biological medicines. 

Read more